Details

Autor(en) / Beteiligte

• Cui, Yong
• Yang, Zhigang
• Wang, Hongxiang
• Yan, Yong
• Huang, Qilin
• Gong, Zhenyu
• Hong, Fan
• Zhang, Xu
• Li, Weiqing
• Chen, Juxiang
• Xu, Tao

Titel

Identification of CDKL3 as a critical regulator in development of glioma through regulating RRM2 and the JNK signaling pathway

Ist Teil von

• Cancer science, 2021-08, Vol.112 (8), p.3150-3162

Ort / Verlag

Tokyo: John Wiley & Sons, Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Wiley Online Library Journals

Beschreibungen/Notizen

• Glioma is one of the most commonly diagnosed intracranial malignancies. The molecular mechanism underlying the development of glioma is still largely unknown. In this study, we present the first report concerning the function and mechanism of cyclin‐dependent kinase‐like 3 (CDKL3) in the development and prognosis of glioma. It is shown that CDKL3 was upregulated in glioma tissues and could independently predict poor prognosis of patients. Silencing CDKL3 in glioma cells could inhibit cell proliferation and migration and induce cell apoptosis and cell cycle arrest, whereas the overexpression of CDKL3 promoted cell proliferation. The in vivo experiments also indicated that knockdown of CDKL3 significantly suppressed tumor growth of glioma. Gene expression profiling of CDKL3 knockdown U87 cells identified RRM2 as a potential target of CDKL3, which was proved to have direct interaction with CDKL3. Given similar effects on glioma development with CDKL3, knockdown of RRM2 could rescue the effects of CDKL3 overexpression on glioma cells. Moreover, knockdown of CDKL3 or RRM2 suppressed the activity of JNK signaling, whereas CDKL3 overexpression produced the opposite effect. In conclusion, our results identified CDKL3 as a promotor for glioma, probably through the regulation of RRM2 and activation of the JNK signalling pathway, highlighting the significance of CDKL3 as a promising therapeutic target of glioma. Our results identified cyclin‐dependent kinase‐like 3 (CDKL3) as a tumor promotor for glioma, probably through the regulation of RRM2 and activation of the JNK signaling pathway. Our data reveal the role of CDKL3 in glioma, highlighting the significance of CDKL3 as a putative therapeutic target.